Ingredient comparison
NMN (nicotinamide mononucleotide) vs Resveratrol
Head-to-head on our evidence, safety, and hype axes - decisive where the data separate, honest where they do not. Not medical advice.
- Ev
- 48
- Safety
- 68
- Hype
- 82
NAD+ precursor marketed for aging; human trials are growing but long-term outcomes remain unproven and regulatory status has been messy.
Full verdict →- Ev
- 52
- Safety
- 74
- Hype
- 78
Polyphenol famous from rodent ‘longevity’ headlines; human translation is limited and interactions exist.
Full verdict →At a glance
Both live in longevity influencer stacks with more biomarker excitement than hard outcome proof in healthy adults. Regulatory status and trial sponsorship patterns differ by molecule. Cancer and pregnancy contexts deserve extra caution before experimenting with NAD-pathway modulators for fun.
Overview
NMN (nicotinamide mononucleotide): NMN is scientifically interesting NAD biology with early human pharmacokinetics trials; anti-aging claims exceed established clinical endpoints.…
Resveratrol: Resveratrol is a cautionary lesson in exciting animal science with underwhelming human outcome replication so far.…
Composite scores are tight (52 vs 56 overall). The breakdown below matters more than a single headline number.
Key differences
Derived from score gaps and verdict bands - not brand marketing.
- Evidence scores are within 6 points (48 vs 52) - neither ingredient clearly dominates trial breadth in our rubric.
- Safety headroom looks comparable (68 vs 74) at typical contexts - personal interactions and conditions still dominate.
- Hype gap is similar (82 vs 78); treat aggressive marketing skeptically for both.
- Both map to the same verdict band (“Mixed evidence”), so the comparison is mostly about axis-level trade-offs, not label drama.
Comparison table
Higher is better for overall, evidence, and safety. For hype gap, lower is better (less marketing ahead of trials).
| Metric | NMN (nicotinamide mononucleotide) | Resveratrol | Lean |
|---|---|---|---|
| Overall | 52 | 56 | Too close to call |
| Evidence | 48 | 52 | Too close to call |
| Safety | 68 | 74 | Too close to call |
| Hype gap | 82 | 78 | Too close to call |
| Verdict | Mixed evidence | Mixed evidence | Same band |
Lean: Overall: Too close to call · Evidence: Too close to call · Safety: Too close to call · Hype gap: Too close to call · Verdict: Same band
Evidence comparison
Human trial breadth and quality for the outcomes people actually shop for - compressed from each hub.
NMN (nicotinamide mononucleotide)
Emerging small human studies; mostly biomarkers and tolerability rather than hard outcomes.
Resveratrol
Human trials show pharmacologic effects on some biomarkers; long-term clinical benefit claims are not established.
Safety comparison
Tolerability, vulnerable groups, and interaction signals we flag at typical contexts of use.
NMN (nicotinamide mononucleotide)
Short-term tolerability often okay in trials; long-term safety in young healthy users is not established.
Resveratrol
Generally tolerated; bleeding and drug interaction discussions at higher doses.
Hype comparison
Where storefront and social claims outrun what trials support - higher hype gap means more disconnect.
NMN (nicotinamide mononucleotide)
Very high hype relative to outcome trials.
Resveratrol
Historically very high anti-aging hype.
Who each is better for
Heuristic fit from our rubric - not personalized medical advice. Check each hub for avoid lists and interactions.
- Nobody for proven life extension - only research contexts so far
- Research curiosity - not a proven longevity intervention for healthy adults
Bottom line
Call it a split decision on the composite: NMN (nicotinamide mononucleotide) and Resveratrol land too close to crown one ingredient outright. Per-axis scores cluster - mechanism fit, tolerance, and clinician context should drive the choice. Read both full verdict pages before changing doses or stacking; our scores compress complexity and are not medical advice.
Full ingredient write-ups
Mechanisms, dosing notes, avoid lists, and sources live on each hub.